Feeds:
Posts
Comments

Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category


Potential interest in LPBI Group’s BioMed e-Series 

Advisor: Conxa Catot · BDM, ex-Elsevier

 

Conxa Catot · BDM
CONTENT ED NET
conxa.catot@contentednet.com
+34 639 357 643
Avda. Josep Tarradellas, 8, 4-4

08029 Barcelona, Spain

 

LPBI Group’s BioMed e-Series – 18 Volumes in Medicina and Life Sciences

Series A: e-Books on Cardiovascular Diseases

                    6 Volumes

Series B: Frontiers in Genomics Research

                    2 Volumes

Series C: e-Books on Cancer & Oncology

                    2 Volumes

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology

                    4 Volumes

Series E: Patient-Centered Medicine – LINKS to e-Books & Cover Pages for Volumes 1,2,3,4

                    4 Volumes

Advice offered by Conxa Catot · BDM, ex-Elsevier

 

  • Panamericana to offer the ebooks

https://www.medicapanamericana.com/

  • Springer Nature

https://www.springernature.com/la

  • Exlibris Group was purchased by Proquest

https://exlibrisgroup.com/

  • Proquest

https://about.proquest.com/

Ana Neira ana.neira@proquest.com and offer your ebooks and contents; she will forward you to the right contact in case they have interest.

  • ebook platform from Proquest

https://ebookcentral.proquest.com/

 

Read Full Post »


e-Voices Podcasting by LPBI: Celebrating Podcast #3 in an Audio Library on leading Scientists and Key Opinion Leaders in Biological Sciences

Authors: Aviva Lev-Ari, PhD, RN

 

2.0 LPBI had published today its third Podcast uploaded to our Cloud at WordPress.com

https://pharmaceuticalintelligence.com/audio-podcasts/

  • Our three podcasts are about the careers of Leaders in Science and Medicine featured in LPBI’s emerging PODCAST LIBRARY, under development.
  • Podcasting Library represents an initiative of Dr. Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN as expressing on 1/25/2016:

Launching LPBI’s, Fourth Line of Business (D): FIVE Podcasts – Audio Series in BioMed

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

  • Since 2019 this initiative is under the leadership of Gail S. Thornton
  • Audio Podcasts represent Strategy #3 in 2020-2021 Vision for 2.0 LPBI
  • Development Plan for e-VOICES Podcasting, 2019 – 2021* is presented in

https://pharmaceuticalintelligence.com/audio-podcasts/

 

 Interviewer
Interviewees
Topic
yr
media
2019

&

2020
 
 
 
Gail S.
Thornton
Dr. Stephen J.
Williams,
Dr. Irina Robu &
Dr. Aviva Lev-Ari
3D BioPrinting in
Medicine
’19
Audio
Gail S.
Thornton
Prof. Feldman
Evolution Biology
and
Population Genetics
’20
Audio
Gail S.
Thornton
Dr. Larry H.
Bernstein,
MD, FCAP
Life Memoirs in
Clinical
Pathology 
’20
Audio
Narrator:
Dr. S.J. Williams
Gail S.
Thornton
Dr. Sudipta Saha
Research in
Reproductive
Technology
’20
Audio
2021
 Gail S.
Thornton
Dr. Justin D.
Pearlman,
MD, PhD
Cardiac Imaging –
Evolution of
Diagnostic
Methods
’21
Audio
Gail S.
Thornton
Dr. Raphael Nir
From Big Pharma to
Biotech
Entrepreneurship
’21
Audio
Gail S.
Thornton
Dr. Meg Baker
GlycoBiology in
Practice
’21
Audio
Gail S.
Thornton
Dr. Ofer Markman
Memories of
Procognia
’21
Audio
Gail S.
Thornton
Dr. Irina Robu
AI & Tissue
Engineering
’21
Audio
Gail S.
Thornton
Dr. Williams
Preferably 3rd 
party
interviewer
sourced
by Gail
AI & Genomics 
’21
Audio
Gail S.
Thornton
Dr. Aviva Lev-Ari
Preferably 3rd 
party
interviewer
sourced
by Gail
Curation & ML
’21
Audio

 

PODCAST #3:

Dear Dr. Saha,

I enjoyed very much the Podcast uploaded today on your Career in Biological Sciences.

Learning about your career by watching the Podcast was a special experience in comparison to reading your CV in 2012 and inviting you to join the Team of EAWs at LPBI.

  • I am so glad that I invited you then and had uploaded your CV to our Cloud on September 9, 2012 at 8:02 pm 
  • I am very happy that we have completed in BioMed e-Series: Volume #17 on Reproductive Genomic and Endocrinology 
  • I have initiated and launched that volume as an opportunity to put together the majority of your contributions in this domain on our Journal

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology

Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types

https://pharmaceuticalintelligence.com/biomed-e-books/series-d-e-books-on-biomedicine/series-d-volume-4-human-reproductive-system-genomic-endocrinology-and-cancer-types/

Book Structure

 

Sudipta Saha, PhD

Larry H. Bernstein,

MD, FCAP

Stephen J. 

Williams, PhD

Aviva

Lev-Ari, PhD, RN

TOTAL

# Articles

24

37

5

20

Enjoy the podcast

###

PODCAST #2:

Dear Dr. Larry,

Your PODCAST represents an amazing career in Medicine

I have uploaded your CV on Sep 9, 2012 at 19:59 pm

Since 2012 till the end of 2016 – you were 

  • LPBI’s Chief Scientific Officer, 
  • Author/Curator of 1,400 articles 
  • Content Consultant on 4 of our 5 e-Book e-Series 
  • Editor of 15 e-Books of our 17 e-Books
  • Single Author of 3 of the 17 e-Books

I am indebted to all your contributions to 1.0 LPBI’s Portfolio of Intellectual Properties

Enjoy the podcast!

Please click here to listen to an expanded life and times of Larry H. Bernstein, M.D. FCAP

###

 

PODCAST #1:

Dear Prof. Feldman,

Your podcast is carrying the voice of an amazing Scientist in Evolution Biology, 

among the top 10 World renown contributors to this field

 

I have uploaded your CV on  September 9, 2012 at 9:38 am

  • We met in 9/1987 when I was a newly minted Berkeley, PhD working at SRI International and you were and still are at Stanford University
  • You followed my career since then, ~35 years
  • I thank you for your contributions to LPBI and your support of my initiatives

Enjoy the podcast!

Future podcasts will feature scientists, clinicians and researchers behind some of the most exciting medical and scientific advances in the world. 

Podcast 2020-02-14 Gail Thornton Interviews Prof. Marcus Feldman by Leaders in Pharmaceutical Business Intelligence

Read Full Post »


Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities

Author: Aviva Lev-Ari, PhD, RN

 

For your New Opportunity in 2021: Management, MarkComm and Scientific/Technical

CONTACT

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

 

DESCRIPTION

https://pharmaceuticalintelligence.com/vision/

 

Announcement

Strategic Transition from 1.0 LPBI to 2.0 LPBI on

 1/1/2021

 

We have transitioned from

  • 1.0 LPBI was an electronic Scientific Publisher, 2012 – 2020

to

  • 2.0 LPBI a Medical Text Analysis (NLP-ML-AI) – SaaS and Content Monetization (Blockchain) – BaaS. A new company profile, 2021 – 2025

Our New NEEDS in Business Development and M&A – Pursue with results:

  • Equity Sharing based

Opportunities Map in the Acquisition Arena

Our New NEEDS in Marketing Communication, Media & PR – Produce new Digital mediums

  • Equity Sharing based
  1. The Announcement of 2.0 LPBI Launch
  2. NEW Website for 2.0 – Initiative #2
  3. Podcast – Strategy #4 – we wish to publish 2 Podcasts per quarter
  4. Planning Advertisement for Amazon Books using Amazon Advertising
  5. NEW documentation on Strategy #2 – Monetization of Journal Articles
  6. NEW documentation on Strategy #2 – Monetization of other IP Asset Classes
  7. NEW documentation on Strategy #1, #3, #6
  8. Reporting on developments in Strategy #5: Joint Ventures & Partnership

Our New Scientific/Technical Opportunities in Natural Language Processing (NLP), Machine Learning (ML) and Artificial Intelligence (AI)

 

Seeking 10 Students INTERNS for a major Medical Text Analysis using NLP, ML, AI

This is a ONE year VIRTUAL STUDENT INTERNSHIP for

  • Computer Science & Biological Sciences or
  • PreMed students
  • PostDocs will develop the interpretation for the hyper-graphs

This internship is not fee for service – but voluntary and offers

  • Mentorship by Scientists
  • Letter of recommendation
  • Opportunity to publish with lead authors
  • Hands on experience with software
  • Opportunities to present in corporate business meetings
  • Scientific Career guidance
  • Access to contacts in Academe and Industry

 

DESCRIPTION

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

 

 

Read Full Post »


Two Site Map Proposals for LPBI’s New Web Site

Curators: Gail S. Thornton, PhD(c) and Aviva Lev-Ari, PhD, RN

Site Map Version 1: Proposal by Aviva

2021-2025: 2.0 LPBI SITE MAP

2.0 LPBI:

  • Executive Summary
  • Vision
  • Brochure
  • Team’s Profiles on Knowledge Portals System

 

PRODUCTS, 2021 – 2025

  • Digital Text & Image Products

6,000 Articles

Article Abstract in WordClouds Images [2020 Summer Internship]

Gallery of +5,000 Biological Images

  • Audio Products: Development stage

Articles in SoundCloud files

Audio Books in Medicine

Biotech & Medical Conference e-Proceedings

Tweet Collections

  • BioMed e-Series Electronic Books in Foreign Languages: Development stage

Japanese

Spanish

Russian

 

SERVICES, 2021 – 2025

  • Insights as a Service [IaaS]: 2021 Medical Text Analysis using NLP, ML, AI
  • Blockchain as a Service [BaaS]: Content Trade using Transactions System for a Digital Store on a Healthcare Marketplace functioning as an Exchange 
  • e-Voices Podcasting
  • Drug Discovery using Synthetic Biology – JV
  • Customer Surveys

AI/ML/NLP PORTALS, 2021 – 2025

  • Genomics
  • Cancer
  • Cardiovascular
  • Metabolomics, Immunology & Endocrinology 
  • Coronavirus & Infectious Diseases
  • Precision Medicine
  • Blockchain in Healthcare

ABOUT 2021 – 2025

  • Testimonials
  • Board Members
  • Founder
  • Quarterly Newsletters: 1/1/2021
  • Current News: 1/1/2021 
  • Calendar: 1/1/2021
  • Connect With Us                            Email           LinkedIn

               Twitter

               Facebook

2012-2020 REFERENCE Record on 2.0 LPBI SITE MAP

https://pharmaceuticalintelligence.com/

1.0 LPBI: 

  • Executive Summary
  • Brochure
  • History
  • VISTA for Exit
  • Our Team of Contributors, 2012 – 2020
  • Investor Relations

 

  • DIGITAL PRODUCTS

Journal PharmaceuticalIntelligence.com: 6,000 articles

BioMed e-Series: e-Books

Press Coverage: e-Proceedings

Social Media Coverage: Tweet Collections

 

  • BUSINESS SERVICES 

Funding, Deals & Partnerships

Healthcare Investor’s Corner

 

ABOUT  2012 – 2020

  • Testimonials
  • Board Members
  • Founder
  • Quarterly Newsletters, 2018 – 2020
  • Current News, 2012-2020
  • Calendar, 2012-2020 
  • Contact us

@@@@@

 

Site Map Version 2: Proposal by Gail S. Thornton

Draft updated: 11/30/2020

Site Map

Connect With Us                  Search

           Email

           LinkedIn

           Twitter

           Facebook

 

Leaders in Pharmaceutical Business Intelligence Group

 

Note: Our Company, Our Services, Our Commitment are major buckets in this order.

 

Our Company                           Our Services 

            About Us                                           Pharmaceutical e-journal

            Leadership

                        Board Members                   AI / ML: Genomics, Cancer

                        Executive Team                    Biomed e-books

            History                                                          Audio and Foreign language 

            Locations                                          Conference e-Proceedings

            Testimonials                                     Podcasts

                                                                       Newsletters

                                                                       Coronavirus portal

                                                                       Medical text analysis

                                                                       Blockchain technology

                                                                       Calendar                                                                     

Our Commitment

            LPBI 2.0

                        Executive Summary

                        Vision

                        Brochure

                        Knowledge Portals

 

            LPBI 1.0

                        Executive Summary

                        Vision

                        Brochure

 

            Summer Internship Program

                        WordCloud article abstracts

 

            Drug Discovery

                        Joint ventures

 

            Investor Relations

            Health care Investors’ Corner            

            Customer Surveys

@@@@

Read Full Post »


Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V

Author: Aviva Lev-Ari, PhD, RN

 

UPDATED on 1/18/2021 – adding data fields or DBs for Content monetization

The hyper-graphs and the Tree Word are including all words – that does not affect the revealed SIGNIFICANT words.

  1. We include all of the NEW runs in the POWERPOINT Presentation

We need to present YOUR PowerPoint on 

  • 1/20 Zoom with NLP Vendor
  • 1/22 Zoom with Blockchain Vendor

All the iterations are needed for as to test the concepts of the 16 articles – ALSO on

A. One article and all the OTHER articles in ONE CHAPTER in ONE Book, I.e., Genomics Volume 1, Chapter 1

B. One article and other articles included in the MAIN Research Category this article was assigned to by the Author

We will need Hyper-graphs and Tree Diagrams for A and for B, above – THEN

  • we will decide on 2.0 LPBI standard: Hyper-graphs or Tree Diagrams as the INPUT for Domain Knowledge Expert’s Interpretation.

C. Announcing Proof-of-Concept for Genomics and Cancer is COMPLETE and CLOSED.

D. Enumeration of all artifacts in one “STANDARD 2.0 LPBI Medical Text Analysis OPERATION” [by Code Author: Madison Davis]

  1. WordCloud
  2. Bar graph
  3. Hyper-graph or Tree Diagram – ONE to be decided to make to the Standard
  4. Text – Interpretation by Domain Knowledge Expert for 1,2,3, above

E. Announcement of Scaling up Project by BioMed e-series: A, B,C, D, E

  • using the “STANDARD 2.0 LPBI Medical Text Analysis OPERATION” [Standard was developed by the Proof-of-Concept.

 

UPDATED on 1/18/2021 – adding features to Content monetization

We are 2.0 LPBI

1. Medical Text Analysis

2. Content monetization

IF

3rd party requests services we did in 1.0 LPBI

THEN

We offer the service for a fee and the monetization will be held by the Blockchain transaction system

Thus, we need to guide our IT Vendor designer of our Blockchain features platform to DESIGN the LEDGER to include few additional categories such as:

1. Consulting Services – Fee for Service

Types of Service:

1.1 Implementation of Medical Text Analysis for Pharma

1.2 Implementation of Medical Text Analysis for Healthcare Insurers

2. Response by 2.0 LPBI to Requests to promote content by 3rd party: 

2.1 Co-marketing of a Conference organized by 3rd Parties – promotion on LPBI Channels

2.2 LPBI to Publish 3rd Party contents, i.e., Articles by guest authors: Payment based on # of views every 90 days at $30 per view

3. Consulting on Media development

3.1 Conference organization

3.2 Book content development

3.3 Real time Press coverage

UPDATED on 1/13/2021

  • We will have from our IT Vendor a BLUEPRINTS for the content monetization system design with all the components laid out in a workflow for a production process to incorporate two sources of data:

1.0 LPBI four IP Asset classes: I, II, III, V will be available for monetization 

The Design include all monetization Features to incorporate the 2.0 LPBI NEWLY TO BE CREATED PRODUCTS by NLP integrated at the article level with the 1.0 LPBI IP.

We will generate four Text Analysis products, like the FOUR outcomes of NLP included in the Proof-of-Concept: 

NLP Products: Will be available for monetization as 2.0 LPBI IP: 

  1. WordClouds, 
  2. Bar charts, 
  3. Hyper-graphs and 
  4. Expert Interpretation in English and Foreign Languages

PHASE I: All Articles in ALL Books at the Chapter Level – THEY WILL HAVE: 

  1. WordClouds, 
  2. Bar charts, 
  3. Hyper-graphs and 
  4. Expert Interpretation in English and Foreign Languages

For:

Series A:  6 volumes, 

Series B:  2 volumes

Series C:  2 volumes

Series D:  4 volumes – 1, 2&3 in one Book, 4

Series E:  4 volumes

Total 17 Books for 18 Volumes

PHASE II: All Articles Not in Books and Not as e-Proceedings – – THEY WILL HAVE: 

  1. WordClouds, 
  2. Bar charts, 
  3. Hyper-graphs and 
  4. Expert Interpretation in English and Foreign Languages

PHASE III: 60 e-Proceedings + 36 Tweet Collections – – THEY WILL HAVE: 

  1. WordClouds, 
  2. Bar charts, 
  3. Hyper-graphs and 
  4. Expert Interpretation in English and Foreign Languages

PHASE IV: 5,100 Biological Images -– THEY WILL HAVE: 

  1. WordClouds, 
  2. Bar charts, 
  3. Hyper-graphs and 
  4. Expert Interpretation in English and Foreign Languages

UPDATED on 1/5/2021

  • WE ARE ARE DOING THE PROOF-OF-CONCEPT in house with INTERNS on a one year Internship on a volunteer basis.
  • My intent was to TEAM UP with AWS and one of their PARTNERS to REDO the POC on the VERSION that XXX has in the NLP Software and with that Partner jointly to Present to the INSURER and secure a contract for that PARTNER that will scale up from
  • (a) 16 articles on Genomics to Volume 1 and Volume 2 Genomics Books and
  • (b) 16 articles on Cancer to Volume 1 and Volume 2 Cancer Books.
  • Hoping in the following phase of the relations with the INSURER –
  • they will be interested in all medical indications covered in our 16 Books (#17 due 1/11/2021) – Namely, they have Patients with Heart problems – LPBI has 6 Volumes in Cardiovascular, books on Immunology, Infectious disease, Metabolic, Endocrine and 4 volumes on Precision Medicine.
    • We mean to use the POC as a Lead toward having the INSURER involved in performing Medical Text Analysis on our 17 books
    • Since they will be the first to get access to the outcomes of such a massive NLP, ML-AI on 17 books
    • They will get access to Hyper-graphs and Domain Expert Interpretations for their INTEREST in Drug substitution and Cost containment and access to our TEAM for ad hoc genomics challenges.
  • The full scale implementation of the POC on all the content in the books requires a PARTNER with expertise and a platform for NLP 
  • It was my intent to find that PARTNER at XXX and its system of Partnerships
  • Our alternative is to Team up with another player in the NLP arena that is not AWS – in the case that XXX can’t team us up with their NLP capabilities
  • WE have approached XXX because our architecture REQUIRES INTEGRATIONS OF THE RESULTS on Medical Text Analysis
  1. WordCloud (Images files),
  2. Hyper-graphs (graph files),
  3. Interpretation of Hyper-graphs (Text file in English and in several Foreign Languages)
  • WITH A CONTENT MONETIZATION SYSTEM that is to be designed for our journal articles, Books, e-Proceedings, Tweet Collections, Biological images

 

  • Such an Integration will allowing for a

Customer to be able to request to review

(a) articles on Topic x

(b) receive from the system 12 top articles

(c) select one or more

(d) pay for them

(e) download the articles they paid for

Expand (a) to (e) to Books, e-Proceedings, Tweet Collections, Biological images

(a) to (e) represents 1.0 LPBI IP

 

  • Such an Integration will allowing for a

Customer to be able to request to review 

(f) WordClouds = Article ABSTRACTS

(g) Hyper-graphs

(h) Domain Expert Interpretations

(I) Interpretations in Few Foreign Languages

Customer will receive from the RECOMMENDATION engine 12 WordClouds of related top articles

Customer will receive from the RECOMMENDATION engine 12 Hyper-graphs of related top articles or one or more research categories

(j) Customer will select one or more

(k) pay for them

(l) download the WordClouds they paid for

(m) Download the HyperGraph they paid for

(n)  Download the Domain Expert Interpretations for the hyper-graph(s)

(o)  Select for the Interpretations to be in one of Few Foreign Languages the system offer

 (j) to (o) represents 2.0 LPBI IP

THE NEEDS OF LPBI IS for ONE INTEGRATED SYSTEM THAT CONTAINS:

(a) to (e) represents 1.0 LPBI IP

AND

(j) to (o) represents 2.0 LPBI IP

AND

CONTENT MONETIZATION SYSTEM with features such as:

PERMISSIONS, LEDGER, RECOMMENDATION ENGINE

It may be the case that YYY has competence in monetization system design BUT DOES NOT currently have what LPBI needs in the Text Analysis with NLP, ML-AI

  • As a result XXX needs to pair us up with one additional XXX-Partner in the space of Text Analysis with NLP, ML-AI – to understand our requirements and to enable scaling up from POC to all the 17 Volumes in Medicine
  • YYY’s Monetization design needs to be INTEGRATED with the the system design for Text Analysis with NLP, ML-AI done by a second AWS partner
  • THEN
  • Hosting on XXX needs to be discussed
  • LPBI’s IP Asset Classes: I,II,III,V –  journal articles, Books, e-Proceedings, Tweet Collections, Biological images – FIT very well AWS Marketplace
  • Please introduce us to the XXX contact for discussion on LPBI and XXX Market place
  • See, Priority #3, Below and due to Priority #1 & #2
  • It seems to be the case that the DEVELOPMENT efforts are expansive for a venture like LPBI, therefore I requested to receive a POINTER to the XXX Venture Acquisition department/team/one person

 

  • Aviva: We need a Partner to Use our Content and use NLP, ML-AI to execute the SEMANTIC Medical Text Analysis to convert TEST to WordClouds and to Hyper-Graphs
  • if YYY can declare expertise in the Medical Text Analysis with NLP, ML-AI
  • If not, XXX may introduce us to another XXX Partner that can handle for LPBI Priority #1, below

 

  • Aviva: We need a Partner to design CONTENT MONETIZATION for existing content AND for the RESULTS of the Medical Text Analysis

 

EXPLANATIONS:

All of the above MUST bring all parties to an understanding of the NEEDS that LPBI has:

PRIORITY #1:

Medical Text Analysis using NLP, ML-AI

  1. LPBI has a Proof-of-Concept in Medical Text Analysis using NLP, ML-AI – will be completed mid Feb. 2021
  2. LPBI has a Client – a Healthcare Insurer interested in Genomics and Cancer and potentially, because they are also a HMO, in all other medical indications covered in LPBI BioMed e-Series – 17 BOOKS
  3. To present to this client (and to other Healthcare Insurers) – LPBI needs one  IT Partner in Medical Text Analysis using NLP, ML-AI able to GET a contract from the INSURER for using the POC to SCALE UP to 2 books in Genomics and 2 books in Cancer – desirable – to be followed up by the remaining (17 – 4) = 13 Books

PRIORITY #2 and PRIORITY #3: need to be running in parallel

PRIORITY #2

DESIGN and ENABLEMENT of Content Monetization for

(a) EXISTING digital products and

(b) the results of PRIORITY #1, above: Medical Text Analysis using NLP, ML-AI

  1. LPBI needs a Content Monetization System (CMS) that we believe YYY has the competences to design
  2. Continuing of progress on this design need to take place
  3. LPBI needs a Proposal and costs of monetization system design for presentation to IB and other funding sources
  4. LPBI is anticipating 3rd parties that will invest in IT infrastructure development.
  5. LPBI created a e-Scientific Publishing venture second to none – based on ~2MM Views has projected revenues to $ZZZ MM
  6. The Content Monetization Cloud-based IT System DESIGN needs to satisfy the following:
  7. THE NEEDS OF LPBI are of ONE INTEGRATED SYSTEM THAT CONTAINS:

[(a) to (e) represents 1.0 LPBI IP] – existing products 
AND 
[(j) to (o) represents 2.0 LPBI IP] – to be developed by NLP, ML-AI of the existing products
AND 
ENABLES CONTENT MONETIZATION of the two sources with features such as:
PERMISSIONS, LEDGER, RECOMMENDATION ENGINE

PRIORITY #3

DESIGN of CONTENT PROMOTION campaigns

  1. XXX Advertising is a company of XXX.com
  2. We need to be teamed up with a Partner or an inside Group to XXX for the DESIGN of CONTENT PROMOTION campaigns for (a) to (e) represents 1.0 LPBI IP [digital products: journal articles, e-Proceedings, Tweet Collections, Biological images]
  3. Upon progress with (j) to (o) represents 2.0 LPBI IP = the results of Text Analysis with NLP, ML-AI 
  4. We need to be teamed up with a Partner or an inside Group to XXX for the DESIGN of CONTENT PROMOTION campaign for WordClouds, Hyper-graphs and Domain Expert Interpretation of the Hyper-graphs in foreign languages

 

UPDATED on 1/4/2021

SPECIFICATION for the Road Map toward an Architecture for Monetization of Content at LPBI

1 – Data entry done by 2.0 LPBI Team of Interns 

2 – Data entry done by IT Vendor

3 – Architecture will be for monetization of 1.0 LPBI IP Asset Classes I,II,III,V

and for

4 – Architecture will also include the infrastructure for the data generated by Medical Text Analysis with NLP, ML, AI done on 1.0 LPBI IP Asset Classes I,II,III,V – called Results of Text Analysis

5. Results of Medical Text Analysis with NLP, ML, AI will include the following Databases (DB):

PHASE I: 

IP Asset Class II – e–Books

  • WordClouds for all articles in 17 BioMed e-Series BOOKS – [Image file – DB]
  • Number of words of which each WordCloud was built on [Text file – DB]
  • Hyper-grapah for articles in each Chapter in the book [Graph file – DB]
  • DomainExpert interpretation of the Hyper-graphs  [English Text file – DB]

1. TITLES of each article in the eTOCs of a Book across all books will be TRANSLATED into Spanish, Japanese, Russian [Text file – DBs, one per language]

2. One page of Domain Expert interpretation of the Hyper-graphs will be TRANSLATED into Spanish, Japanese, Russian  [Text file – DBs, one per language]

 

PHASE II:

Scale up PHASE I – from IP Asset Class II [all articles in 17 Books]  TO all the articles in the Journal = IP Asset Class I

 

PHASE III:

Scale up from PHASE I: from All Books (IP Asset Class II) and PHASE II: all the articles in the Journal (IP Asset Class I)

TO 

  • IP Asset Class III (e-Proceedings/Tweet Collections), 

 

PHASE IV:

  • IP Asset Class V (Biological Images)

 

UPDATED on 1/2/2021

Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2021/01/01/announcing-strategic-transition-from-1-0-lpbi-to-2-0-lpbi-on-1-1-2021-new-management-and-new-technical-opportunities/

 

We have transitioned from

  • 1.0 LPBI was an electronic Scientific Publisher, 2012 – 2020

to

  • 2.0 LPBI a Medical Text Analysis (NLP-ML-AI) – SaaS and Content Monetization (Blockchain) – BaaS.

 

  • A new company profile, 2021 – 2025

 

Content Monetization has TWO distinct parts:

 

2.1   Belongs to 1.0 LPBI: exist in WordPress.com cloud EXISTING digital IP asset classes: Articles, Books, e-Proceedings/Tweet Collections, biological images

2.2   Belongs to 2.0 LPBI: will be created by Text Analysis with NLP. ALL NEW TO BE CREATED digital IP asset classes by 2.0 LPBI as a result of Strategy #1: Text Analysis using NLP, ML, AI:

2.2.1 WordClouds – a DB of all images created by NLP one per article. This will be IP Asset Class 11, will belong to 2.0 LPBI (1 to 10, exist and belong to 1.0 LPBI)

2.2.2 Hyper-graphs – a DB of all graphs,  the hyper-graphs created by NLP. This will be IP Asset Class 12, will belong to 2.0 LPBI.

Examples:

  • One hyper-graph for articles in a Book Chapter x 20 Chapter per one book x 17 books
  • One hyper-graph for articles in Categories on the Journal ontology
  • N=730 categories

2.2.3 English Text interpretation of each Hyper-graph – a DB of text Interpretations linked to DB of graphs and DB of Images. This will be IP asset Class 13, belongs to 2.0 LPBI

These Text interpretations of hyper-graphs will be translated to foreign languages. Example, Spanish, Japanese

ONE DB of Text interpretations per one language

 

2.0 LPBI had several IT infrastructure needs:

A.  Infrastructure for Text Analysis with NLP of all IP assets in 2.1

B.  Monetization infrastructure for IP Assets of 2.1, above

C.  Monetization infrastructure for IP Assets of 2.2, above

 

System integration of A, B, C

My understanding is that you wish to address B.

Leaving A and C for later.

My view is:

  • B and C are one project because a USE CASE called A Journal Article Profile needs to have all the data fields I covered, in the e-mail, below 2.1 plus 2.2, as above. The architecture for B and C are inseparable – Meta data needs to be comprehensive
  • A – Infrastructure for Text Analysis needs to be developed in parallel to the Content Monetization B and C.

If All what 2.0 LPBI will do will be

  • monetization of Content generated, 2012-2020 – it’s valuation will be x

Versus

2.0 LPBI

(a) A Medical Text Analysis Company – SaaS and a

(b) Content Monetization Company – Blockchain as a Service (BaaS)

 

2.0 LPBI distinct competitive advantages are:

  1. we created content we own it vs applying NLP on PubMed.
  2. we create Value-Add by NLP with Expert INTERPRETATION in multi languages
  3. We monetize digital content
  4. We monetize WordClouds “image files and Hyper-graphs “graph files”

 

System Integration job needed for 2.0 LPBI includes the following:

  1. Our IP on WordPress needs to be migrated into a Cloud Computing environment of an INTEGRATOR i.e.,
  • AWS
  • DELL
  • Other
  1. That integrator needs to have the two technologies we need:

Strategy #1: Text Analysis by ML

  • Medical Text Analysis SW: NLP, ML, AI

This is Strategy #1 for 2.0 LPBI, namely

Conversion of 3.2 Giga bites of English Text into Hyper-graphs of Semantic content relationships for applications such as:

– drug discovery (needed by Big Pharma)

– drug repurposing (needed by Big Pharma)

– drug substitution & cost containment (needed by Healthcare Insurers)

 

Strategy #2: Content Monetization by Blockchain IT infrastructure features:

  • Permission granting to download content on a cyber-secure IT platform
  • immutable LEDGER – recording payments
  • Recommendation Engine: choose one or more article from this list of 12
  • Blockchain SW: Transaction network for Ledger, Immutability, Recommendation engine and Permission to download

This is Strategy #2 for 2.0 LPBI, namely

Content monetization requires IT infrastructure

We understand that 2.0 LPBI need to

  • partner

or

  • be acquired by a 3rd party

(a) to invest in the IT needed for content monetization of

1.0 LPBI IP asset classes: I, II, III, IV

2.0 LPBI IP novel asset classes such as

IP Asset Class 11: WordClouds

(image file DB)

IP Asset Class 12: Hyper-graphs

(graph file DB)

IP Asset Class 13: Domain Expert interpretation of Hyper-graphs

(text file DB, one DB for a Language, expert interpretation translated in several languages)

 

  1. 2.0 LPBI Strategy #1: Medical Text Analysis (NLP, ML, AI) (SaaS)

and

  1. 2.0 LPBI Strategy #2:  Monetization of Text Analysis Results as Products (Blockchain as a Service (BaaS))

and

  1. LPBI & A2C-AWS regarding Strategy #1: NLP
  2. LPBI & A2C-AWS regarding Strategy #2: Monetization

I believe that the definition for the Profile of an Article I am providing below will clarify matters more and your feedback will be helpful.

1.0 LPBI had created 6,000 articles in need for monetization

2.0 LPBI is launching Six new initiatives the relations of four of the six are tied with the definition of an Article PROFILE, as below.

  • The monetization INFRASTRUCTURE needs to accommodate TWO types of Digital Products:

(a) The existing Journal articles

(b) The RESULTS generated from Journal articles being subjected to TEXT ANALYSIS with NLP, ML, AI

Therefore we need to address:

C.  LPBI & A2C-AWS regarding Strategy #1: NLP on 1.0 LPBI Text

D.  LPBI & A2C-AWS regarding Strategy #2: Monetization

 

Let’s start with C.

LPBI & A2C-AWS regarding Strategy #1: NLP on 1.0 LPBI Text

 

It seems that AWS has technologies in place for A2C to use for performing Medical Text Analysis using AWS NLP, ML, AI on 1.0 LPBI’s 6,000 articles

– Thus, we need to explore HOW we can use AWS NLP, ML, AI technologies and produce for 2.0 LPBI the following Text Analysis features:

[they are derived from our Proof-of-Concept is on–going]

5.3 Does the article have the Text Analysis features which are obtained by performing text analysis with NLP:

5.3.1.  a WordCloud – needs to be stored in graph file of WordClouds

5.3.2.  # words used

5.3.3.  Hyper-graphs – need to be stored in graph file of Hyper-graphs

5.3.3.1 One Hyper-graph for All articles in a Book Chapter

5.3.3.2 One Super-graph for All articles in one or more Categories of Research  – need to be stored in graph file of Super-graphs

5.3.4.  Domain Expert interpretation for 5.3.3.

5.3.4.1 Domain Expert interpretation for 5.3.3.1 – performed by 2.0 LPBI Experts generating Text files

5.3.4.2 Domain Expert interpretation for 5.3.3.2 – performed by 2.0 LPBI Experts generating Text files

 

Let’s continue with D.

LPBI & A2C-AWS regarding Strategy #2: Monetization

A2C will design a Cloud-based IT Infrastructure that will enable monetization of two types of products:

Type One: 1.0 LPBI Asset Classed I, II, III, V

  • Below is the Profile Definition for the Unit Case: A Journal Article (1.0 LPBI Asset Classed I) – See below
  • Same Profile Definitions needs to be done for 1.0 LPBI Asset Classed II (books), III (e-Proceedings/Tweet Collections), V (Gallery of 5,100 Images) – PENDING

Type Two: POST Medical Text Analysis using NLP, ML, AI – the following NEW PRODUCTS are created and NEED TO BE MONETIZED

Text Analysis features to be produced by NLP, ML, AI:

5.3.1. a WordCloud – needs to be stored in graph file of WordClouds

5.3.2. # words used

5.3.3. Hyper-graphs  – need to be stored in graph file of Hyper-graphs

5.3.3.1 One Hyper-graph for All articles in a Book Chapter

5.3.3.2 One Super-graph for All articles in one or more Categories of Research  – need to be stored in graph file of Super-graphs

5.3.4. Domain Expert interpretation for 5.3.3.

5.3.4.1 Domain Expert interpretation for 5.3.3.1 – performed by 2.0 LPBI Experts generating Text files

5.3.4.2 Domain Expert interpretation for 5.3.3.2 – performed by 2.0 LPBI Experts generating Text files

BASED on the definition provided, below, suggested steps by 2.0 LPBi are the following:

  • A2C-AWS and 2.0 LPBI will generate a PROPOSAL for AWS to fund that effort for future placement in AWS Marketplace
  • A2C-AWS and 2.0 LPBI will develop Plans and Cost Structures of the infrastructure needed for CONTENT monetization – to be presented to Investment Banker in NYC
  • A2C-AWS and 2.0 LPBI will take the LPBI Proof-of-Concept on Medical Text Analysis with NLP in Genomic and Cancer and will create jointly TWO skeleton IT Structures

#1 Skeleton IT Structure: 

Reproduce the Proof-of-Concept using AWS – NLP–ML-AI technology and Scale up to One Chapter in Genomics Volume 1 and One Chapter in Cancer Volume 2

That will be JOINTLY presented at a Healthcare Insurer [LPBI’s Contact] by LPBI AND A2C-AWS – with the scope of getting a Contract that A2C-AWS will define, execute and manage the Statement Of Work (SOW) and submit Costs to the Healthcare Insurer. Prospects of expansion to Cardiovascular and Immunology, beyond Genomics and Cancer are strong.

 

#2 Skeleton IT Structure: 

Produce a Skeleton for Monetization of 

  • 0 LPBI – Journal articles AND 
  • 0 LPBI — the Results of #1 Skeleton IT Structure: PRODUCTION OF FEATURES of TEXT ANALYSIS using AWS NLP technologies

That will be presented at 

  • an Investment Banker in NYC [LPBI’s Contact], 

and 

  • by LPBI 

to other funding sources, and 

  • by A2C-AWS to other funding sources, Chiefly, AWS – internally.

             

The Opportunities MAP written on 2/2019 for LPBI M&A or Exit include

Twelve Economic Segments for LPBI Group’s IP – Prospects for Transfer of Ownership

  1.     Holding Companies, Investment Bankers and Private Equity
  2.     Information Technology Companies – Health Care
  3.     Scientific Publishers
  4.     Big Pharma
  5.     Internet Health Care Media & Digital Health
  6.     Online Education
  7.     Health Insurance Companies & HMOs
  8.     Medical and Pharma Associations
  9.     Medical Education
  10.     Information Syndicators
  11.     Global Biotech & Pharmaceutical Conference Organizer
  12.     CRO & CRA 

Information Technology Sector: Cloud-based – 

Amazon Web Services (AWS),  Alphabet – Verily, Apple-Health,  IBM Watson

Information Technology SectorCloud & Server-based – 

Microsoft-Health, Dell Boomi, Oracle-Health, SAP, Intel-Health

 

Please review this LINK:

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

 

For the DESIGN of IT Infrastructure for Monetization, the following is an essential 

DEFINITION of a USE CASE for “PROFILE of an Article”: 

 

1.0 LPBI BEGINS 

Monetization of 6,000 Digital Products – USE CASE: A Journal Article

5.0 Article Title

5.0.1 Article URL

5.0.2 Author 1: Name

5.0.2.1 Author 2: Name

5.0.2.2 Author 3: Name

5.0.2.3 Author 4: Name

5.0.3  Date of Publication

5.0.4  # Words

5.0.5  # Views since Published to DATE

 

5.1 Is the article in a Book?

5.1.1 Article is not in a Book only in the Journal

5.2 Article is in a Book – In which one(s)?

5.2.1 LPBI Series A

5.2.1.1 Volume 1

5.2.1.2 Volume 2

5.2.1.3 Volume 3

5.2.1.4 Volume 4

5.2.1.5 Volume 5

5.2.1.6 Volume 6

5.2.2   LPBI Series B

5.2.2.1 Volume 1

5.2.2.2  Volume 2

5.2.3   LPBI Series C

5.2.3.1 Volume 1

5.2.3.2 Volume 2

5.2.4   LPBI Series D

5.2.4.1 Volume 1

5.2.4.2 Volume 2

5.2.4.3 Volume 3

5.2.4.4 Volume 4 [Dr. Williams and Dr. Irina are adding editorials, NOW]

5.2.5   LPBI Series E

5.2.5.1 Volume 1

5.2.5.2 Volume 2

5.2.5.3 Volume 3

5.2.5.4 Volume 4

 

1.0 LPBI ENDS

2.0 LPBI BEGINS

Strategy #1: Medical Text Analysis (NLP, ML, AI) (SaaS)

and 

Strategy #2: Monetization of Text Analysis Results as Products (Blockchain as a Service (BaaS)

5.3 Does article have the Text Analysis features:

5.3.1.a WordCloud – needs to be stored in graph file of WordClouds

5.3.2. # words used

5.3.3. Hyper-graphs  – need to be stored in graph file of Hyper-graphs

5.3.3.1 One Hyper-graph for All articles in a Book Chapter

5.3.3.2 One Super-graph for All articles in one or more Categories of Research  – need to be stored in graph file of Super-graphs

5.3.4.  Domain Expert interpretation for 5.3.3.

5.3.4.1 Domain Expert interpretation for 5.3.3.1 – Translated into few other languages

5.3.4.2 Domain Expert interpretation for 5.3.3.2 -– Translated into few other languages

 

5.4 Audio File added to Article

5.4.1 In place – Audio file type [Text to Audio]

5.4.2 SoundCloud file

 

5.  Article Titles was translated to

5.5.1   Spanish

5.5.2   Japanese

5.5.3   Russian

 

6.   Article Interpretation of Hyper-graphs was translated to

5.6.1   Spanish

5.6.2   Japanese

5.6.3   Russian

The content below was not Updated on 1/2/2021

Distinction between A and B, below

 

  • A.  1.0 LPBI – 2012–2020 – IP Assets available for sale

  • B.  2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE

 

A.  1.0 LPBI – 2012–2020 – IP Assets available for sale

 

A.1 A List of Scientific articles N=6,000 

STORED in Excel file run on 6/30/2020 and 12/31/2020

 

They need to be Indexed by several keys:

A.1.1  Author Name

A.1.2  Article Title

A.1.3  Category of Research, see article example , below

For the Cancer category

  • we have the following tree structure
  • System had data on how many articles are in each category
  •  Cancer – General
  •  Cancer and Current Therapeutics
    •  interventional oncology
      •  Breast Cancer – impalpable breast lesions
      •  Prostate Cancer: Monitoring vs Treatment
  •  CANCER BIOLOGY & Innovations in Cancer Therapy
    •  Anaerobic Glycolysis
    •  Cachexia
    •  Cancer Genomics
      •  Circulating Tumor Cells (CTC)
        •  Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood
          •  mRNA
        •  MagSifter chip
      •  KRAS Mutation
      •  Li-fraumeni syndrome.
      •  TP53 – Germline mutations
    •  cancer metabolism
    •  Funding Opportunities for Cancer Research
    •  Genomic Expression
    •  Glioblastoma
    •  Hexokinase
    •  Loss of function gene
    •  Metabolic Immuno-Oncology
    •  Metastasis Process
    •  Methylation
    •  Microbiome and Responses to Cancer Therapy
    •  Monoclonal Immunotherapy
    •  mtDNA
    •  Oxidative phosphorylation
    •  Pancreatic cancer
    •  Pyruvate Kinase
    •  The NCI Formulary
    •  tumor microenvironment
    •  Warburg effect
  •  Cancer Informatics
  •  Cancer Prevention: Research & Programs
  •  Cancer Screening
  •  Cancer Vaccines: Targeting Cancer Genes for Immunotherapy
    •  Engineering Enhanced Cancer Vaccines

A.1.4  Type of article: by the role of the author: 

  • If the Author is Curator THAN this article is a curation
  • If the Author is Reporter THEN this article is a Scientific reporting article

A.1.5  Article Abstract will be a WordCloud created by ML – one image per article

Example

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?  <<<<<<<<< Article Title

Author: Larry H. Bernstein, MD, FCAP  <<<<<<<<< Author’s Name

https://pharmaceuticalintelligence.com/2012/10/17/is-the-warburg-effect-the-cause-or-the-effect-of-cancer-a-21st-century-view/   <<<<<<< URL

  • The system provides: “Related” what you named associated, see below  will need to be placed in the article description
  • The system provides: “Posted in” – meaning  ALL the categories of research checked off by the author that this article belong to by the SUBJECT MATTER of the article

EXAMPLE for Related” what you named associated

Related

What can we expect of tumor therapeutic response?

In “Biological Networks, Gene Regulation and Evolution”

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

In “Academic Publishing”

AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo

In “Biological Networks, Gene Regulation and Evolution”

Examples for >>>>>>>> Category of Research  live links listing in parenthesis number of articles in one category

Posted in Biological NetworksCANCER BIOLOGY & Innovations in Cancer TherapyCell BiologyDisease BiologyGenome BiologyImaging-based Cancer Patient ManagementInternational Global Work in PharmaceuticalLiver & Digestive Diseases ResearchMetabolomicsMolecular Genetics & PharmaceuticalNutritionPharmaceutical Industry Competitive IntelligencePharmaceutical R&D InvestmentPopulation Health ManagementProteomicsStem Cells for Regenerative MedicineTechnology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphateATPGlycolysisHypoxia-inducible factorsKrebLactate dehydrogenaseMammalian target of rapamycinMitochondrionWarburg Effect | 40 Comments

Below, an excerpt from the 6,000 LIST: Top Posts by VIEWS for all days ending 2020-06-02 (Summarized)

 

All Time      
Title Views Author Name Type of Article
Home page / Archives 676,690 Internet Access Tabulation
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 17,117 Larry H. Bernstein, MD, FACP Investigator Initiated Research
Recent comprehensive review on the role of ultrasound in breast cancer management 14,242 Dr. D. Nir Commission by Aviva Lev-Ari, PhD, RN
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 13,839 Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN Commission by Aviva Lev-Ari, PhD, RN
Paclitaxel vs Abraxane (albumin-bound paclitaxel) 13,709 Tilda Barliya, PhD Investigator Initiated Research
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications 8,230 Aviva Lev-Ari, PhD, RN Investigator Initiated Research
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 7,903 Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN Investigator Initiated Research
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) 6,540 Tilda Barliya, PhD Investigator Initiated Research
Our TEAM 6,505 Internet Access Tabulation
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects 5,221 Larry H. Bernstein, MD, FACP Investigator Initiated Research
Interaction of enzymes and hormones 4,901 Larry H. Bernstein, MD, FACP Commission by Aviva Lev-Ari, PhD, RN
Akt inhibition for cancer treatment, where do we stand today? 4,852 Ziv Raviv, PhD Investigator Initiated Research
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation 4,535 Stephen J. Williams, PhD Investigator Initiated Research
The History and Creators of Total Parenteral Nutrition 4,511 Larry H. Bernstein, MD, FACP Commission by Aviva Lev-Ari, PhD, RN
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses 4,365 Zohi Sternberg, PhD Investigator Initiated Research
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules 4,188 Stephen J. Williams, PhD Investigator Initiated Research
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets 4,038 Dr. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FACP & Aviva Lev-Ari, PhD, RN Commission by Aviva Lev-Ari, PhD, RN
Founder 3,895 Aviva Lev-Ari, PhD, RN Investigator Initiated Research

EndFragment

A.2 A List of 16 e-BOOKS

https://lnkd.in/ekWGNqA

 

A.2.1   Each book is made of articles included in the N=6,000

A.2.2 Books will list the URL of each book

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

https://www.amazon.com/dp/B07MGSFDWR

https://www.amazon.com/dp/B07MKHDBHF

https://www.amazon.com/dp/B08385KF87

A.3 A List of e-Proceedings and Tweet Collections

A.3.1 each entry is an article included in N=6,000

B.   2.0 LPBI – 2021–2025 –

IP Assets under construction –

WILL BE AVAILABLE FOR SALE

 

B.1 Journal articles

  • Will be subjected to ML and a NEW product will be created
  • Instead of N=6,000 article – we will have N= 6,000 Medical INSIGHTS

B.2 16 e-Books

  • Will be subjected to ML and a NEW product will be created
  • Instead of 16 Books – we will have 16 COLLECTIONS of Medical INSIGHTS derived from Text Analysis of ONLY the articles included on each Volume
  • 16 e-Books will become 16 AUDIO BOOKS
  • 16 e-Books will become 16 Books in Japanese, Spanish and Russians

 

B.3 eProceedings & Tweet collections

  • Will be subjected to ML and a NEW product will be created
  • Instead of 60 e-Proceedings and 30 Tweet collections we will get 100 Business INSIGHTS Collections in the domain of each conference

 

We believe that Blockchain will enable STORAGE of each item that will be available for sale

  • LPBI will have team members Bundling items per customer needs 
  • Promotion can be done OUTSIDE the Blockchain system – STIRRING Customers to the Blockchain transaction system for TRADE and recording of transactions
  • That is true for A and for B, below

A.   1.0 LPBI – 2012–2020 – IP Assets available for sale

B.   2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE

 

Data Architecture Questions

 

  1. In what data format is the content stored? In other words, is the content in image pdfs, searchable document pdfs, html, xls, word documents, text files, or some other form?

Example: TEXT

Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words

My proposed Elevator Pitch

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers ~6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 16 books have been downloaded ~125,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

    • We UPLOAD MS Word file NOT PDF
    • INVENTORY is stored in Excel
    • Top Posts for all days ending 2020-11-16 (Summarized)
      1. 7 Days |30 Days |Quarter |Year |All time
    • All Time
  • Title
  • Views
  • 716,030
  • 17,263
  • 15,300
  • 14,341
  • 14,006
  • 8,770
  • 8,398
  • 6,632
  • 6,580
  • 5,536
  • 5,304
  • 5,056
  • 4,899
  • 4,712
  • 4,665
  • 4,453
  • 4,416
  • 4,335
  • 4,206
  • 4,126
  • 4,118
  1. Within each content file or dataset, is the content metadata already defined, or would we need to parse the file to pull out the metadata? In other words, in the file for a journal article, do you already have the author, date, abstract, keywords, etc. defined as discrete pieces of data, or is all of this information embedded within the overall file?

YES

They need to be Indexed by several keys:

A.1.1  Author Name

A.1.2  Article Title

A.1.3  Category of Research

 

  1. Do you expect to use a single type of subscription (such as a monthly subscription), or will different types of data have different types 

of subscription options (similar to how journals offer both one-time 24-hour subscriptions to a single article as well as monthly ongoing subscriptions)?

We wish to SELL ARTICLE DOWNLOAD vs Subscriptions

  1. Does the marketplace need to include fuzzy search (i.e., the ability to find content based on “similar to” criteria, instead of just exact match searches)? Does it need to present the user with related content, or only the content that was searched for?

Our system attaches to each article RELATED content

  1. We assume that the marketplace is not intended to replace your current LPBI company website? We are not scoping the quote to include a full website rebuild; it is assumed that the marketplace is separate (and your users would access the marketplace via the LPBI website).

YES – the digital store will connect to our newly to be designed web site for 2.0 LPBI on WordPress.com

  • The digital store is the FORUM to buy goods by digital download of content
  • $30 for One digital article or Audio article
  • REFERRAL to Amazon Website to buy a book or the book in AUDIO format or a book in Japanese and Spanish – Russia is not served by Amazon – we can sell directly to consumers
  • $100 download of an e-Proceedings for a Conference or the Tweet collection

For 2.0 LPBI Products

Bundles of Insights for Targeted Industries – B–to-B

  • Tier #1:  Insights for drug discovery embedded in consulting engagements
  • Tier #2:  Insights for drug repurposing embedded in consulting engagements
  • Tier #3:  Insights for Health Care Insurers embedded in consulting engagements

Bundles of insights for theScientific Community – B–to-C

Read Full Post »


The Nobel Prize in Chemistry 2020: Emmanuelle Charpentier & Jennifer A. Doudna

Reporters: Stephen J. Williams, Ph.D. and Aviva Lev-Ari, PhD, RN

 

UPDATED on 11/12/2020

Harvard’s Jack Szostak congratulates former advisee Jennifer Doudna

It was a toast from one Nobel laureate to another, sweetened by the pride of a mentor to a prized student.

When Jennifer Doudna Ph.D. ’89 was honored on Wednesday with the Nobel Prize in chemistry for her work on the CRISPR gene-editing technique, she became the second person to gain such an honor from the lab of Jack Szostak, a genetics professor at Harvard Medical School and Massachusetts General Hospital, and professor of chemistry and chemical biology at Harvard’s Faculty of Arts and Sciences.

Szostak, who won the Nobel Prize in physiology or medicine in 2009 for work on how telomere caps keep the body’s chromosomes from breaking down, advised Doudna’s doctoral work on RNA and on Wednesday raised a glass in honor of Doudna, now at the University of California, Berkeley. In a tweet, Szostak expressed his delight at seeing someone he once guided through her early scientific steps soar to science’s highest reaches:

Doudna received the prize together with Emmanuelle Charpentier, for their work discovering and developing CRISPR as a precise gene-editing tool. In just the eight years since the pair announced their discovery the use of the technique has rapidly spread to a host of fields, allowing researchers to alter the code of life and develop resistant crops, new medical therapies, and even anticipate curing inherited diseases.

 

UPDADTED on 11/2/2020

 

Announcement of the Nobel Prize in Chemistry 2020

Live webcast from the press conference where the Royal Swedish Academy of Sciences will announce the Nobel Prize in Chemistry 2020.

 

 

The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2020 to

Emmanuelle Charpentier
Max Planck Unit for the Science of Pathogens, Berlin, Germany

Jennifer A. Doudna
University of California, Berkeley, USA

“for the development of a method for genome editing”

Genetic scissors: a tool for rewriting the code of life

Emmanuelle Charpentier and Jennifer A. Doudna have discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants and microorganisms with extremely high precision. This technology has had a revolutionary impact on the life sciences, is contributing to new cancer therapies and may make the dream of curing inherited diseases come true.

Researchers need to modify genes in cells if they are to find out about life’s inner workings. This used to be time-consuming, difficult and sometimes impossible work. Using the CRISPR/Cas9 genetic scissors, it is now possible to change the code of life over the course of a few weeks.

“There is enormous power in this genetic tool, which affects us all. It has not only revolutionised basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments,” says Claes Gustafsson, chair of the Nobel Committee for Chemistry.

As so often in science, the discovery of these genetic scissors was unexpected. During Emmanuelle Charpentier’s studies of Streptococcus pyogenes, one of the bacteria that cause the most harm to humanity, she discovered a previously unknown molecule, tracrRNA. Her work showed that tracrRNA is part of bacteria’s ancient immune system, CRISPR/Cas, that disarms viruses by cleaving their DNA.

Charpentier published her discovery in 2011. The same year, she initiated a collaboration with Jennifer Doudna, an experienced biochemist with vast knowledge of RNA. Together, they succeeded in recreating the bacteria’s genetic scissors in a test tube and simplifying the scissors’ molecular components so they were easier to use.

In an epoch-making experiment, they then reprogrammed the genetic scissors. In their natural form, the scissors recognise DNA from viruses, but Charpentier and Doudna proved that they could be controlled so that they can cut any DNA molecule at a predetermined site. Where the DNA is cut it is then easy to rewrite the code of life.

Since Charpentier and Doudna discovered the CRISPR/Cas9 genetic scissors in 2012 their use has exploded. This tool has contributed to many important discoveries in basic research, and plant researchers have been able to develop crops that withstand mould, pests and drought. In medicine, clinical trials of new cancer therapies are underway, and the dream of being able to cure inherited diseases is about to come true. These genetic scissors have taken the life sciences into a new epoch and, in many ways, are bringing the greatest benefit to humankind.

Illustrations

The illustrations are free to use for non-commercial purposes. Attribute ”© Johan Jarnestad/The Royal Swedish Academy of Sciences”

Illustration: Using the genetic scissors (pdf)
Illustration: Streptococcus’ natural immune system against viruses:CRISPR/Cas9 pdf)
Illustration: CRISPR/Cas9 genetic scissors (pdf)

Read more about this year’s prize

Popular information: Genetic scissors: a tool for rewriting the code of life (pdf)
Scientific Background: A tool for genome editing (pdf)

Emmanuelle Charpentier, born 1968 in Juvisy-sur-Orge, France. Ph.D. 1995 from Institut Pasteur, Paris, France. Director of the Max Planck Unit for the Science of Pathogens, Berlin, Germany.

Jennifer A. Doudna, born 1964 in Washington, D.C, USA. Ph.D. 1989 from Harvard Medical School, Boston, USA. Professor at the University of California, Berkeley, USA and Investigator, Howard Hughes Medical Institute.

SOURCE

https://www.nobelprize.org/prizes/chemistry/2020/press-release/

 

Nobel Prize in Chemistry awarded to scientists who discovered CRISPR gene editing tool for ‘rewriting the code of life’

(CNN)The Nobel Prize in Chemistry has been awarded to Emmanuelle Charpentier and Jennifer A. Doudna for the development of a method for genome editing.

They discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants and micro-organisms with extremely high precision.
Before announcing the winners on Wednesday, Göran K. Hansson, secretary-general for the Royal Swedish Academy of Sciences, said that this year’s prize was about “rewriting the code of life.”
The American biochemist Jennifer A. Doudna (left) and French microbiologist Emmanuelle Charpentier, pictured together in 2016.
 
The CRISPR/Cas9 gene editing tools have revolutionized the molecular life sciences, brought new opportunities for plant breeding, are contributing to innovative cancer therapies and may make the dream of curing inherited diseases come true, according to a press release from the Nobel committee.
 
 
There have also been some ethical concerns around the CRISPR technology, however.
Charpentier, a French microbiologist, and Doudna, an American biochemist, are the first women to jointly win the Nobel Prize in Chemistry, and the sixth and seventh women to win the chemistry prize.
close dialog

 

Jennifer Doudna wins 2020 Nobel Prize in chemistry

 

First Day in a Nobel Life: Jennifer Doudna

12,365 views
Oct 7, 2020
 
Scenes from day that UC Berkeley Professor Jennifer Doudna won the Nobel Prize For the full story, visit: https://news.berkeley.edu/2020/10/07/… University of California, Berkeley, biochemist Jennifer Doudna today won the 2020 Nobel Prize in Chemistry, sharing it with colleague Emmanuelle Charpentier for the co-development of CRISPR-Cas9, a genome editing breakthrough that has revolutionized biomedicine. CRISPR-Cas9 allows scientists to rewrite DNA — the code of life — in any organism, including human cells, with unprecedented efficiency and precision. The groundbreaking power and versatility of CRISPR-Cas9 has opened up new and wide-ranging possibilities across biology, agriculture and medicine, including the treatment of thousands of intractable diseases. Doudna and Charpentier, director of the Max Planck Institute for Infection Biology, will share the 10 million Swedish krona (more than $1 million) prize. “This great honor recognizes the history of CRISPR and the collaborative story of harnessing it into a profoundly powerful engineering technology that gives new hope and possibility to our society,” said Doudna. “What started as a curiosity‐driven, fundamental discovery project has now become the breakthrough strategy used by countless researchers working to help improve the human condition. I encourage continued support of fundamental science as well as public discourse about the ethical uses and responsible regulation of CRISPR technology.” Video by Clare Major & Roxanne Makasdjian
SOURCE

 

Jennifer Doudna wins 2020 Nobel Prize in chemistry

 

Jennifer Doudna in the PBS Movie CRISPR

Our critically-acclaimed documentary HUMAN NATURE is now streaming on NETFLIX. #HumanNatureFilm. Find out more about the film on our website.

 

Other Articles on the Nobel Prize in this Open Access Journal Include:

2020 Nobel Prize for Physiology and Medicine for Hepatitis C Discovery goes to British scientist Michael Houghton and US researchers Harvey Alter and Charles Rice

CONTAGIOUS – About Viruses, Pandemics and Nobel Prizes at the Nobel Prize Museum, Stockholm, Sweden 

AACR Congratulates Dr. William G. Kaelin Jr., Sir Peter J. Ratcliffe, and Dr. Gregg L. Semenza on 2019 Nobel Prize in Physiology or Medicine

2018 Nobel Prize in Physiology or Medicine for contributions to Cancer Immunotherapy to James P. Allison, Ph.D., of the University of Texas, M.D. Anderson Cancer Center, Houston, Texas. Dr. Allison shares the prize with Tasuku Honjo, M.D., Ph.D., of Kyoto University Institute, Japan

2017 Nobel prize in chemistry given to Jacques Dubochet, Joachim Frank, and Richard Henderson  for developing cryo-electron microscopy

2016 Nobel Prize in Chemistry awarded for development of molecular machines, the world’s smallest mechanical devices, the winners: Jean-Pierre Sauvage, J. Fraser Stoddart and Bernard L. Feringa

Correspondence on Leadership in Genomics and other Gene Curations: Dr. Williams with Dr. Lev-Ari

Programming life: An interview with Jennifer Doudna by Michael Chui, a partner of the McKinsey Global Institute

Read Full Post »


The 40th Anniversary of SRI ORGANON TOASTMASTERS virtual celebration on Tuesday, August 18, 11:45 a.m.-1:00 p.m

Past Member of SRI Organon Toastmasters, 5/1985 – 9/1988: Aviva Lev-Ari, PhD, RN

 

I was a Competent Toastmasters working on the Distinguished Toastmasters rank.

Today, 8/7/2020 was invited to attend the SRI Organon Toastmasters 40th Anniversary. 

The picture on my Student ID Card at University of California, Berkeley, 9/1978 – 12/1983

 

From: NAOMI LEVENSON <na8mi@comcast.net>

Date: Friday, August 7, 2020 at 3:38 PM

Subject: SRI Organon Anniversary

SRI Organon Toastmasters turned 40 in February!

We invite you to join the virtual celebration on Tuesday, August 18, 11:45 a.m.-1:00 p.m.

https://us02web.zoom.us/j/83888447143

 

More information is on the attached flyer.

Plan to come to the meeting early and stay afterwards. There will be time to reminisce and catch up.

Do you have any memories you might want to share. You can add your thoughts, anecdotes and comments on   https://tinyurl.com/yxl4nuu4.

Bring your own beverage for the TOAST!

Please plan to attend.

Naomi Levenson

 

40th Anniversary Flyer (1)

Read Full Post »


LPBI Group’s Founder – A Profile for a Wikipedia Entry

Curator: Zach Day, with editorial comments by Prof. Marcus W. Feldman, Dr. Joel T. Shertok, PhD and Gail S. Thornton, PhD(c), MA

 

Aviva Lev-Ari, Ph.D., R.N.

 

 

Aviva Lev-Ari, Ph.D., R.N., is the founder of Leaders in Pharmaceutical Business Intelligence Group (LPBI Group), a Newton, Massachusetts, start-up company launched in 2012 in the domain of Pharmaceutical Media.

The LPBI Group incorporates into three interrelated domains:

  • an open-access online scientific journal,
  • a series of 16 BioMed e-books covering five specialties of Medicine and Life Sciences (Cardiovascular, Genomic Medicine, Cancer, Immunology and Precision Medicine) and
  • real-time press coverage of BioMed scientific and medical conferences.

Year over year, LPBI Group continues to increase its readership of medically valuable content, which includes more than 5,800 scientific articles with over 1.8 million views in its online scientific journal. The LPBI Group goal is to make scientific content universally accessible to the pharmaceutical media and electronic scientific publishing communities.

https://pharmaceuticalintelligence.com/ at @pharma_BI and @AVIVA1950. Additionally, the 16 BioMed e-books can be accessed on the website: https://pharmaceuticalintelligence.com/biomed-e-books/ and on https://lnkd.in/ekWGNqA

Please visit the LPBI Group Wikipedia page to learn more about our company. [ZACH: CAN YOU PUT A LINK TO THE LPBI GROUP Wikipedia Page here?] 

Ongoing Commitment to Life Sciences

The LPBI Group team curates life sciences and medical literature producing clinical interpretations of scientific findings and publishing the results as articles in LPBI Group’s open-access online scientific Journal http://pharmaceuticalintelligence.com.

Dr. Lev-Ari serves as Editor-in-Chief of the Journal and of the series of 16 BioMed e-books. The e-Books cover five cardinal Medical specialties https://lnkd.in/ekWGNqA. The books serve physicians in the community, allied healthcare professionals, medical students and an extensive global community of e-readers in life sciences and biomedicine. The books are also included in the medical curricula of several prominent medical schools in the United States.

The LPBI Group has competencies in real-time coverage of Medical and Biotech global conferences, using methodology developed by Dr. Lev-Ari. This method allows for the generation of e-Proceedings with a single click. Dr. Lev-Ari developed a series of templates used during the Conferences to generate Tweets representing quotes by speakers and their affiliations. To date Dr. Lev-Ari has generated 60 e-Proceedings and 36 Tweet Collections. Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

 

Early Life and Education

Dr. Aviva Lev-Ari was born in Bucharest, Romania, to a Jewish family with a 400-year history in Europe. Along with her father and older sister, Pnina Abir-Am, Ph.D. [Brandeis University], the family moved to Israel in December 1958. [Her mother succumbed to breast cancer in September 1956 when Aviva was 6 years old].  As a young girl in a 10-year-old State of Israel, the new reality was significantly different than that of her European early years. She loved oranges and bananas both of which were rare in Eastern Europe in the 50s. She bonded with the nature and the geography of Israel, the wild flowers of the hilly slopes of Mount Carmel and the wide panoramic view of the Western bound of the Valley of Jezreel from the window of her bedroom shared with her sister. Dr. Lev-Ari graduated with honors from the prestigious private institution, Huggim High School on Mount Carmel, in Haifa in 1968. This gymnasium was established in 1932 by German Jewish emigres, who were former German University Professors, forced to leave their Academic positions by the Nazis.

These high school years made a long lasting impression on Aviva, a studious, achievement–oriented, hardworking student who was motivated to excel in her studies.

Following her IDF military service, she studied at the Hebrew University (HUJI) in Jerusalem for six years, where she earned her B.A. and M.A. degrees (Cum Laude) in Urban Planning and Economic Geography in 1976. At HUJI she became a very scholarly-inclined student, motivated by the outstanding faculty members, i.e., Prof. S. Reichman and Prof. Louis Guttman.

Her Masters thesis applied Facet Theory, SSA, MSA & POSAC, the novel non-parametric paradigm in Statistics developed by Prof. Louis Guttman in 1946 and during the 60s and the 70s, while using the latest version of the computer programs that were included for the 1st year in SPSS in 1976. The thesis was filed with the Graduate Division in July 1976, conferring and confirming the highest GPA recorded at the registrar of the Faculty of Social Sciences at HUJI to-date (95/100).

She then worked at the Technion, which was known to hire chiefly its own graduates, in Applied Research as the first HUJI graduate to be hired. During 1977-1978 at the Technion, she applied Facet Theory in Urban Planning. She came to the United States to pursue her doctoral studies in September 1978. Her postgraduate studies were at the University of California – Berkeley, where she earned her doctorate in 1983 in Industrial Organization Economics and Location Theory under Prof. Allan Pred, a famous AAAG Fellow +40 years of the 20th century on the Faculty at Berkeley, the #2 Department of Geography in the country. The Berkeley academic environment was most conducive for interdisciplinary research and for expression of the highest level of creativity; both were Prof. Allan Pred’s contributions as mentor and as advisor to Aviva. The intellectual stimulation culminated in her Ph.D. thesis, and other milestones beyond the years at Berkeley. Prof. Pred presented a draft of her dissertation at MIT in October 1983. Recollections of Years at UC, Berkeley, Part 1 and Part 2:

  • Recollections: Part 1– My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Prof. Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2– “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

and

Additionally, Dr. Lev-Ari was Prof. Louis Guttman’s student in 1975-76. She was known for applying his methods in the top-tier consulting industry in the United States using the software licensed via Yissum (Technology Transfer Office of HUJI) at SRI International for Fortune 50 companies e.g., GM, Alcan, Rhone Poulenc. At the University of California – Berkeley, she taught upper division courses in Quantitative Methods using SSA, MSA & POSAC in 1979, 1980, 1981. In 1990-91, she was the developer of the models that made a cardinal organizational change from managerial to brokerage agencies by a top financial & insurance firm based in Boston, Massachusetts, where she spent the fall and winter of 1990/91 on the 52nd floor of one of the two tallest skyscrapers in Boston.

While in California, she also studied Organizational Behavior under James G. March and Harold J. Leavitt at Stanford University Graduate School of Business, in an Exchange Program between Berkeley and Stanford in 1980-81.

Autobiographical Annotations: Tribute to My Professors

 

Dr. Lev-Ari worked in the domains of her expertise for 25 years, at several of the most esteemed institutions in the United States, among them, SRI International – Menlo Park, California; MITRE – Bedford, Massachusetts; PSC – Cambridge, Massachusetts (HQS: Dallas, TX); and McGraw Hill – Monterey, California (HQS: NY, NY).

Dr. Lev-Ari reinvented her career toward a new direction in Health Care, by being admitted into the Bouve College of Health Sciences in 2005, and earning a nursing degree at Northeastern University (Nurse Practitioner Direct Entry track – 800 candidates for 26 places.) For comparison, at the Ph.D. Program Admission, there were 240 candidates for 12 places and only 8 earned the degree five years later.

At Northeastern University she researched cardiovascular pharmacotherapy with her professor of Pharmacology for four independent research courses during 2006-2007. Pharmacology was the domain she liked the most at Bouve College. She developed the concept of a combination drug therapy (three agents) for prevention of macro cardiovascular events. She already knew then, that she would return to pharmaceutical study some day.

Career

Reflections on a Four-phase Career

Dr. Lev-Ari’s career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018, has the following phases:

  • Phase 1: Research, 1973 – 1983
  • Phase 2: Corporate Applied Research in the US, 1985 – 2005
  • Phase 3: Career Reinvention in Health Care, 2005 – 2012
  • Phase 4: Electronic Scientific Publishing, 4/2012 to present

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

This article was written in March 2018. It was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/

https://www.afhu.org/2018/05/03/aviva-lev-ari/

Early Career

Dr. Lev-Ari started her career conducting research from 1973 -1983.  She then transitioned into Corporate Applied Research in the United States between 1985-2005.

Second Career

Dr. Lev-Ari reinvented her career in the Health Care arena, and earned her R.N. degree. She worked in Clinical Nursing Management, 2008–2012, in post-acute settings and was Supervisor of a Long-Term Acute Care Hospital (LTACH) in Waltham, Massachusetts.

Recent Career

Dr. Lev-Ari’s most recent transition has been into Electronic Scientific Publishing, from April 2012 to the Present. Currently she is the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group. She is the developer of several curation methodologies for scientific content, and developed a unique methodology for the creation of an electronic Table of Contents (eTOCs). She was initiated into the development of workflow procedures involved in the systematic population of all eTOCs by Expert Editors, that culled articles from the journals’ research categories to create a one of a kind eTOCs for each volume [except for Cancer Volume 1].

In 2012, Dr. Lev-Ari launched, and currently leads the Journal, PharmaceuticalIntelligence.com. She is the Editor in Chief of the Journal and of the BioMed e-Series. The transformative work done at LPBI Group allows cutting-edge biomedical research innovation to be widely disseminated and accessible to the research and the non-research communities. Her method of curation represents a mode of scientific communication including synthesis, analysis, and interpretation.

Experts, authors, and writers add their knowledge and expertise in re-thinking and conceptualizing subjects selected in their domain of expertise, to form new curations or updating existing ones. The books are transformative in their capacity to accelerate diffusion of scientific innovations. To date 115,000 pages have been downloaded form the 16 Volumes.

The curation is done by experts with a perspective within each field, allowing for the creation of scientific content that combines conceptual evolution within the scientific breakthroughs analyzed with their anticipated future implications.

Dr. Lev-Ari’s work is innovative and creative. She has perfected the art of scientific curation for medical evaluation of cutting-edge literature. It is available through LPBI Group’s open access Journal. Dr. Lev-Ari has tutored numerous students and young adults in her career. LPBi is enjoying an excellent reputation within the field, for the valuable information it provides. Dr. Stephen Williams, a Professor of Pharmacology at the Sbarro Health Research Organization at Temple University said of Dr. Lev-Ari,

“I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.” Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized.”

Personal Life

Dr. Lev-Ari married in 1971 a newly minted graduate of the Technion and Officer in the Signal Corps of IDF. Hanoch Lev-Ari, Ph.D., Fellow IEEE, has been a Professor of EE at Northeastern University since 1990. He is a graduate of Stanford University, Ph.D. ’84 in EE, and the Technion, BSEE ’71 & MSEE ’76. They lived in Palo Alto, California from 1978-1990 and in Newton Center, Massachusetts since September 1990. They have one married son, Edan, a 2007 Cornell University graduate working at Natick Lab, Natick, MA

Dr. Lev-Ari enjoys swimming, classical music, Jazz, non-fiction literature, fashion design, fashion photography, orchids and peonies.

Publications

 

Books

Dr. Lev-Ari’s expertise is in Cardiovascular Diseases

https://lnkd.in/e6WkMgF

 

  1. Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms. On comsince 6/21/2013 https://lnkd.in/8DANfq
  2. Cardiovascular Diseases, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation. On comsince 11/30/2015 https://lnkd.in/ekbuNZ3
  3. Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics. On comsince 11/29/2015 https://lnkd.in/ecp5mrA
  4. Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases. On comsince 12/26/2015 https://lnkd.in/dwqM3K3
  5. Cardiovascular Diseases, Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases. On comsince 12/23/2018 https://lnkd.in/e3r87cQ
  6. Cardiovascular Diseases, Volume Six: Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment. On comsince 12/24/2018 https://lnkd.in/e_CTb4R

Editor-in-Chief

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

https://www.amazon.com/dp/B07MGSFDWR

https://www.amazon.com/dp/B07MKHDBHF

https://www.amazon.com/dp/B08385KF87

 

Awards

https://lnkd.in/eEyn69r

Nomination for 2018 Yidan Prize, recognition in the field of medical education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/

  • Dr. Lev-Ari was nominated for the 2020 Campanile Excellence in Achievement Award, December 5, 2019.
  • Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award, December 7, 2018,

Links

https://pharmaceuticalintelligence.com/founder/

https://pharmaceuticalintelligence.com/contributors-biographies/aviva-lev-ari/

https://pharmaceuticalintelligence.com/praising-lpbi/

 

 

 

Read Full Post »


WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN

 

Article Name
Live Link
Views
All Time
Categories of Research 


#1



Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?





17,140Biological NetworksCANCER BIOLOGY & Innovations in Cancer TherapyCell BiologyDisease BiologyGenome BiologyImaging-based Cancer Patient ManagementInternational Global Work in PharmaceuticalLiver & Digestive Diseases ResearchMetabolomicsMolecular Genetics & PharmaceuticalNutritionPharmaceutical Industry Competitive IntelligencePharmaceutical R&D InvestmentPopulation Health ManagementProteomicsStem Cells for Regenerative MedicineTechnology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphateATPGlycolysisHypoxia-inducible factorsKrebLactate dehydrogenaseMammalian target of rapamycinMitochondrionWarburg Effect


#2



Recent comprehensive review on the role of ultrasound in breast cancer management





14,553Biomarkers & Medical DiagnosticsHealth Economics and Outcomes ResearchHealthcare costs and reimbursementImaging-based Cancer Patient ManagementMedical Device Therapies for Altzheimer’s DiseaseMedical Devices R&D InvestmentMedical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound | Tagged breast biopsiesbreast cancerbreast cancer managementbreast cancer screeningbreast cystbreast lesionsbreast ultrasoundmammographyMRIPersonalized medicinePETsupport breast cancertomosynthesisyale university schoolyale university school of medicine 

#3

Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)


13,893Coagulation Therapy and Internal BleedingElectrophysiologyFDA Regulatory AffairsOrigins of Cardiovascular DiseasePharmacotherapy of Cardiovascular Disease | Tagged Academic Medical CenterAmsterdamAnticoagulantApixabanDabigatranDirect thrombin inhibitorDirect Xa inhibitorFood and Drug AdministrationNew England Journal of MedicineNon-steroidal anti-inflammatory drugNortheastern UniversityPRADAXAProthrombin timeRivaroxabanVTEWarfarin 

#4

Paclitaxel vs Abraxane (albumin-bound paclitaxel)cent comprehensive review on the role of ultrasound in breast cancer management


13,878BioSimilarsCANCER BIOLOGY & Innovations in Cancer TherapyDisease Biology, Small Molecules in Development of Therapeutic DrugsNanotechnology for Drug DeliveryPharmaceutical AnalyticsPharmaceutical R&D InvestmentRegulated Clinical Trials: Design, Methods, Components and IRB related issues | Tagged Abraxanealbumin-bound paclitaxelbreast cancerclinical studiesFREE paclitaxellinear PKnon-linear PKPaclitaxelPharmacokineticsPKside effectsTaxol 


#5


Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications

8,367Coagulation Therapy and Internal BleedingFrontiers in Cardiology and Cardiovascular DisordersOrigins of Cardiovascular DiseasePharmacotherapy of Cardiovascular Disease, tagged Dabigatranrivaroxaban and apixaban for stroke prevention in atrial fibrillation 

#6

Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

8,068Medical Devices R&D InvestmentNitric Oxide in Health and DiseaseTechnology Transfer: Biotech and Pharmaceutical | Tagged ARDSAviva Lev-AriInhaled Nitric Oxidenitric oxideprostacyclinPulmonary hypertensionRespiratory failure 
#7

Our Team

6,553LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management 
#8
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)
6,545Advanced Drug Manufacturing TechnologyBio Instrumentation in Experimental Life Sciences ResearchBiological Networks, Gene Regulation and EvolutionBiomarkers & Medical DiagnosticsBioSimilarsCANCER BIOLOGY & Innovations in Cancer TherapyCancer Prevention: Research & ProgramsCell Biology, Signaling & Cell CircuitsDisease Biology, Small Molecules in Development of Therapeutic DrugsHealth Economics and Outcomes ResearchMedical Devices R&D InvestmentNanotechnology for Drug DeliveryPharmaceutical R&D InvestmentPopulation Health Management, Genetics & PharmaceuticalRegulated Clinical Trials: Design, Methods, Components and IRB related issuesTechnology Transfer: Biotech and Pharmaceutical | Tagged Blood testcarbon nanotubesearly detectionMesothelinPancreatic cancer 




#9






Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects










5,235Aortic Valve: TAVR, TAVI vs Open Heart SurgeryBiomarkers & Medical DiagnosticsCell Biology, Signaling & Cell CircuitsChemical Biology and its relations to Metabolic DiseaseCoagulation Therapy and Internal BleedingDisease Biology, Small Molecules in Development of Therapeutic DrugsMetabolomicsMitral Valve: Repair and ReplacementNitric Oxide in Health and DiseasePersonalized and Precision Medicine & Genomic ResearchPharmaceutical Industry Competitive IntelligencePharmacotherapy of Cardiovascular DiseasePopulation Health Management, Nutrition and PhytochemistryProteomics | Tagged anti-inflammatoryanti-TNFAnticoagulantAntithrombinblood flow resistancecell junctionscellular adhesionCoumadinEndothelial cellsFactor IX and IXaFactor VII and VIIaFactor VIII and Factor VIIIaFactor X and XafibrinogenfibrinolysisheparinHypoxia-inducible factorsNon-steroidal anti-inflammatory drugPartial thromboplastin timePhysiologyplasminplatelet aggregationplateletsprothrombinsoluble fibrinsubendothelial matrixThrombinthrombomodulinThrombustissue factorTNF-aVon Willebrand factorWH Seegers 
#10

Interaction of enzymes and hormones

5,173Cell Biology, Signaling & Cell CircuitsChemical Biology and its relations to Metabolic DiseaseMetabolomicsPopulation Health Management, Genetics & PharmaceuticalPopulation Health Management, Nutrition and PhytochemistryReproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics | Tagged active compoundsenzymehormoneinteractionMetabolismTherapy 

#11

Akt inhibition for cancer treatment, where do we stand today?


4,865CANCER BIOLOGY & Innovations in Cancer TherapyCell Biology, Signaling & Cell Circuits | Tagged Cancer researchcancer therapyCell BiologymTORNF-κBPI3K/AKT pathwayPTENSignal transduction 

 

#12

The History and Creators of Total Parenteral Nutrition

 

4,660

 

Disease BiologyGastroenterologyUncategorized | Tagged Amino acidsenteral nutritionNutritionTPN

 

#1

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?

Article #1: WordCloud by DM

#2

Recent comprehensive review on the role of ultrasound in breast cancer management

Article #2: WordCloud by NT

#3

Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

Article #3: WordCloud by ZD

#4

Paclitaxel vs Abraxane (albumin-bound paclitaxel)cent comprehensive review on the role of ultrasound in breast cancer management

Article #4: WordCloud by DM

#5

Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications

Article #5: WordCloud by ZD

#6

Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

Article #6: WordCloud by NT

#7

Our Team

Article #7: WordCloud by DM

Read Full Post »


LPBI’s Accomplishments 1Q 2020 & 2Q 2020

Reporter: Aviva Lev-Ari, PhD, RN

 

1. LPBI’s External Scientific Relations

  • They all are presenting at LPBI’s Monthly Zoom Meetings on 2nd Tuesday of the month, 11AM EST – 2PM EST
  • Among them: SY, AG, YB, RN,
  • Each is serving as a Reference to LPBI for the Exit purpose
  • Each is serving as a Reference to LPBI’s Founder for the Exit purpose

2. LPBI’s External Business relations

  • Among them: Dr. Mak, AB, GG, AA
  • Each is to take a ROLE in the Exit
  • AB & GG will work together

HAPPY to report a WIN: SY will be represented by AB in two top Big Pharma scenes

3.  LPBI’s Internal Reorganization to be announced June 23, 2020

  • Twelve Economic Segments for LPBI Group’s IP – Prospects for Transfer of Ownership

  1.       Holding Company and Investment Banker
  2.       Information Technology Companies – Health Care
  3.       Scientific Publishers
  4.       Big Pharma
  5.       Internet Health Care Media & Digital Health
  6.       Online Education
  7.       Health Insurance Companies & HMOs
  8.       Medical and Pharma Associations
  9.       Medical Education
  10.       Information Syndicators
  11.       Global Biotech & Pharmaceutical Conference Organizer
  12.       CRO & CRA
  • Generic Business side are changing roles to serve Industrial VERTICALS
  • In the Industrial VERTICALS Plan every FIT Member on the Business side and Business-Science side is proposed a Vertical to pursue
  • ACTION POINT: Each Industrial VERTICAL Lead will schedule three meetings between July 10, 2020 and December 20, 2020 for presentation of LPBI by SJW, JTS, ALA to key enterprises in their VERTICAL
  • Proposed Industrial VERTICALS for Business-side to lead are as follows:

RAM:

  • IT sector Cloud-based Amazon Web Services (AWS), Alphabet – Verily, Apple-Health, IBM Watson
  • Server-Cloud: Intel-Health, Microsoft-Health, Oracle-Health, DELL, SAAP

JSZ:

  • Big Pharma: J&J, Roche, Novartis, Pfizer, Bayer, Merck, GSK, Sanofi, Abbvie, Abbott, Eli Lilly, Amgen, BMS, Gilead, AstraZeneca, TEVA, BI, NovoNordisk, Allergen, Takeda+Shire, Celgene, Biogen
  • CROs
  • Internet Health Care Media (MedScape, UptoDate) [work with GST]

JTS:

  • To be announced on 6/23/2020, incoming Board Member
  • Industrial VERTICAL in the Financial Sector:
  1. Holding Companies: Internet Brands of KKR, Temasek, NMC, Generex
  2. Health Insurance Companies & HMOs

GST: Media Content-driven:

  • Information Syndicators
  1. Reuters Clarivate [work with JSZ & JTS] &
  2. Springer [work with SJW]
  • Medical and Pharma Associations

SJW:

  • To be announced on 6/23/2020, incoming Chief Scientific Officer
  • Education Sector
    • Medical Schools

IR: 

  • Education Sector
    • Online Education [work with IR]

OM:

  • Global Biotech & Pharmaceutical Conference Organizers
  • Israel & Europe

THESE announcements will all be included in the new Organization Chart presented in

  • Zoom Meeting on June 23, 2002 at 2PM EST – 5PM EST
  • I am with the Summer Interns 6/23, 11AM EST – 2PM EST
  • Zoom Invitations will go out on 6/22/2020

3. New significant members joined LPBI Team as ACTIVE FIT Members since January 2020:

  • JTS – Industrial VERTICALS: Financial Sector. Effective 6/23/2020 Board Member
  • JSZ – Industrial VERTICALS: Big Pharma & CRO
  • OM – Artificial Intelligence for Text Analysis, 2020 Summer Internship Lead, Industrial VERTICALS: Global Conference Organizers. REGIONS; Israel & Europe
  • DM – Acting CTO

4. THREE or Four Student-Interns for LPBI’s 2020 Summer Internship Program

  • DM – Replied to my AD
  • SS – Sourced by Robin
  • NST – Sourced by Robin
  • ZD – an LPBI Returning Intern from 2019 – Confirmed by e-mail, Updated Resume Upload – PENDING

5. Acting CTO applied for LPBI’s Enterprise Twitter Developer Account.

  • Application approved in two rounds.
  • Daniel uses Teepy & Pyton on CORE Application Development Projects with ALA

6. Data on Twitter shows REACH via 2nd degree at ~18 MM

7. LPBI has two Twitter Handles with combined Followers of +1,000 – @pharma_BI @AVIVA1950

8. LPBI’s Library Slide Deck has 140 slides, each slide has in the footer the initials of slide’s curator. [11 slides are by GST & RAM, 50% by GST].

9. LPBI’s Brochure has 40 Pages – rewritten per Mr. Bahl’s comments. JTS is Owner of that document.

  • Appended comments by JSZ to comments by Mr. Bahl. No use made for betterment of document.

10.  LPBI’s Business Plan serves as venture’s Prospectus. It includes 26 comments by Mr. Bahl, and ALA responses to these comments. This process yielded 22 new pages of content not in existence in version 3/19/2020. Prospectus is 240 pages.

  • Document version 3-19-2020 includes comments by GST, IR, SJW, OM. Computations by JTS, JTS & ALA, ALA and DM & ALA. Tables by OM, ALA & OM, ALA & SJW and charts by JTS.
  • Appended comments by JSZ to comments by Mr. Bahl (85%, “I agree”). No use made for betterment of document.

11. Founder, as Editor-in-Chief, had launched MOST TIMELY AND SWIFTLY on March 14, 2020 the Coronavirus Portal

https://pharmaceuticalintelligence.com/coronavirus-portal/

Eight Pages of LPBI Group’s Coronavirus PORTAL VIEWED by +2,000 e-Readers

  1. Breakthroughs
  2. Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus
  3. An Epidemiological Approach Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN Lead Curators – e–mail Contacts: sjwilliamspa@comcast.net and avivalev-ari@alum.berkeley.edu
  4. Community Impact Stephen J. Williams, PhD and Irina Robu, PhD Lead Curators – e–mail Contacts: irina.stefania@gmail.com and sjwilliamspa@comcast.net
  5. Economic Impact of The Coronavirus Pandemic Dr. Joel Shertok, PhD Lead Curator – e–mail Contact: jshertok@processindconsultants.com
  6. Voices of Global Citizens: Impact of The Coronavirus Pandemic Gail S. Thornton, M.A. Richard A. Mandahl, MBA and Sudipta Saha, PhD Lead Curators – e–mail Contacts: gailsthornton@yahoo.com and rmandahl@gmail.com and sudiptasaha1977@gmail.com
  7. Diagnosis of Coronavirus Infection by Medical Imaging and Cardiovascular Impacts of Viral Infection Dr. Jason Zielonka, MD, AFACC and Aviva Lev-Ari, PhD, RN Lead Curators e-mail contacts: Jasonz.mit@gmail and avivalev-ari@alum.berkeley.edu
  8. Key Opinion Leaders Followed by LPBI Aviva Lev-Ari, PhD, RN and Dr. Ofer Markman, PhD Lead Curators e-mail contacts; oferm2015@gmail.com and avivalev-ari@alum.berkeley.edu

12. AI Portal was launched for LPBI’s New Direction Pipeline in Text Analysis by Machine Learning, NLP, AI on LPBI’s Three CORPUSES: Journal, e-Books, e-Proceedings & Tweet Collections

https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/

13. Knowledge Portals System was launched for Human Resource Management in the iCloud as One Point of Profile View and Performance Review – ALL information on each FIT members to be shared with Prospect Acquirers upon request.

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

14. 2020 Summer Internship PORTAL launched on 6/16/2020 following the Kick off Meeting introducing the interns.

2020 Summer Internship PORTAL is in use by

  • INTERNS – Each has a Personal Page: Daniel M. Sonam S, Noam S-T 
  • DELIVERABLES by INTERNS to be used for a PROOF OF CONCEPT on three types of Cancer from our Journal Articles
  • INSTRACTORS’ Assignments: Lead, OM
  • PRESENTERS PowerPoints: ALA, SJW, IR, OM

https://pharmaceuticalintelligence.com/2020-summer-internship/

Read Full Post »

Older Posts »